PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
76.46
+0.86 (1.14%)
Nov 20, 2025, 4:00 PM EST - Market closed
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $211.01M in the quarter ending September 30, 2025, with 7.23% growth. This brings the company's revenue in the last twelve months to $1.78B, up 97.54% year-over-year. In the year 2024, PTC Therapeutics had annual revenue of $806.78M, down -13.97%.
Revenue (ttm)
$1.78B
Revenue Growth
+97.54%
P/S Ratio
3.36
Revenue / Employee
$1,894,728
Employees
939
Market Cap
6.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
| Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
| Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
| Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
| Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PTCT News
- 20 hours ago - PTC Therapeutics to Host R&D Day - PRNewsWire
- 9 days ago - PTC Therapeutics, Inc. (PTCT) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 15 days ago - PTC Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - PRNewsWire
- 20 days ago - PTC Therapeutics to Participate at Upcoming Investor Conferences - PRNewsWire
- 24 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga